The transforming growth factor-β-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease

Experimental Physiology

Volumn 98, Issue 8, 2013, Pages 1262-1266

  Upton, Paul D ^a   Morrell, Nicholas W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; DISEASE CLASSIFICATION; DISEASE COURSE; GENETICS; HOMEOSTASIS; HUMAN; HYPOXIA; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; SMOOTH MUSCLE FIBER;

EID: 84880699079     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.069104     Document Type: Article

References (30)

1. Aguirre JI, Morrell NW, Long L, Clift P, Upton PD, Polak JM & Wilkins MR (2000). Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 278, L981-L987.
2. Anderson L, Lowery JW, Frank DB, Novitskaya T, Jones M, Mortlock DP, Chandler RL & de Caestecker MP (2010). Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 298, R833-R842.
3. Archer SL, Weir EK & Wilkins MR (2010). Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121, 2045-2066.
4. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC & Morrell NW (2002). Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678.
5. Bertolino P, Deckers M, Lebrin F & ten Dijke P (2005). Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 128, 585S-590S.
6. Coward WR, Saini G & Jenkins G (2010). The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 4, 367-388.
7. Davies RJ, Holmes AM, Deighton J, Long L, Yang X, Barker L, Walker C, Budd DC, Upton PD & Morrell NW (2012). BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol 302, L604-L615.
8. Dorfmuller P, Perros F, Balabanian K & Humbert M (2003). Inflammation in pulmonary arterial hypertension. Eur Respir J 22, 358-363.
9. Frank DB, Lowery J, Anderson L, Brink M, Reese J & de Caestecker M (2008). Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 294, L98-L109.
10. Han C, Hong KH, Kim YH, Kim MJ, Song C, Kim MJ, Kim SJ, Raizada MK & Oh SP (2013). SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension. Hypertension 61, 1044-1052.
11. Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, Li E, Raizada MK, Bloch KD & Oh SP (2008). Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 118, 722-730.
12. Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL & Ikeda K (2006). BMP-7 opposes TGF-β1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol 290, L120-L126.
13. Korchynskyi O & ten Dijke P (2002). Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277, 4883-4891.
14. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK & Morrell NW (2009). Altered bone morphogenetic protein and transforming growth factor-β signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 119, 566-576.
15. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC & Morrell NW (2006). Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98, 818-827.
16. López-Hernández FJ & López-Novoa JM (2012). Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res 347, 141-154.
17. Lowery JW, Frump AL, Anderson L, DiCarlo GE, Jones MT & de Caestecker MP (2010). ID family protein expression and regulation in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 299, R1463-R1477.
18. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA 3rd, Soubrier F, Trembath RC & Chung WK (2009). Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 54, S32-S42.
19. McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Michelakis ED & Archer SL (2007). Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 292, L872-L878.
20. 1 and bone morphogenetic proteins. Circulation 104, 790-795.
21. Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri FM, Peters DM, Dumitrascu R, Seeger W, Knaus P, Schermuly RT & Eickelberg O (2007). Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 27, 1072-1078.
22. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, Bradshaw TY, Southgate L, Lee GJ, Jackson I, Lord GM, Gibbs JS, Wilkins MR, Ohta-Ogo K, Nakamura K, Girerd B, Coulet F, Soubrier F, Humbert M, Morrell NW, Trembath RC & Machado RD (2011). Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 32, 1385-1389.
23. Pegorier S, Campbell GA, Kay AB & Lloyd CM (2010). Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-β1 in normal human lung fibroblasts (NHLF). Respir Res 11, 85.
24. Reynolds AM, Xia W, Holmes MD, Hodge SJ, Danilov S, Curiel DT, Morrell NW & Reynolds PN (2007). Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 292, L1182-L1192.
25. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N & Souza R (2009). Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54, S43-S54.
26. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, Muramatsu M & Fukuchi Y (2006). Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290, L450-L458.
27. Thomas M, Docx C, Holmes AM, Beach S, Duggan N, England K, Leblanc C, Lebret C, Schindler F, Raza F, Walker C, Crosby A, Davies RJ, Morrell NW & Budd DC (2009). Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol 174, 380-389.
28. West J, Tada Y, Fagan KA, Steudel W, Fouty BW, Harral JW, Miller M, Ozimek J, Tuder RM & Rodman DM (2005). Suppression of type II bone morphogenic protein receptor in vascular smooth muscle induces pulmonary arterial hypertension in transgenic mice. Chest 128, 553S.
29. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC & Morrell NW (2005). Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96, 1053-1063.
30. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, Shimoda LA, Neptune E, Higgins L, Murphy A, Chakravarty S, Protter A, Sehgal PB, Champion HC & Tuder RM (2008). Role of the TGF-β/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 177, 896-905.